Notice bibliographique
- Notice
Type(s) de contenu et mode(s) de consultation : Texte noté : électronique
Titre(s) : MicroRNA in human malignancies [Texte électronique] / edited by Massimo Negrini,... George A. Calin,... Carlo M. Croce,...
Publication : London : Academic press, copyright 2022
Description matérielle : 1 ressource dématérialisée
Autre(s) auteur(s) : Negrini, Massimo. Éditeur scientifique
Calin, George A.. Éditeur scientifique
Croce, Carlo M. (1944-....). Éditeur scientifique
Sujet(s) : MicroARN
Indice(s) Dewey :
572.88 (23e éd.) = ARN
Identifiants, prix et caractéristiques : ISBN 9780128222874
Identifiant de la notice : ark:/12148/cb47309540r
Notice n° :
FRBNF47309540
(notice reprise d'un réservoir extérieur)
Table des matières : Intro ; MicroRNA in Human Malignancies ; Copyright ; Contents ; Contributors
; Section A: miRNAs involvement in basic mechanisms of cancer development ; Chapter
1 Overview on miRNA classification, biogenesis, and functions ; Introduction ; MicroRNA
and the complex biological system of gene expression ; MicroRNA biogenesis, nomenclature,
and classification ; Origins of the canonical primary miRNA transcript ; From canonical
primary miRNA to mature miRNA ; Noncanonical miRNA biogenesis and isomiRs ; Nomenclature
and classification ; Mechanisms of miRNA-mediated gene regulation ; Posttranscriptional
regulation of mRNA stability and translation ; Models of miRNA-mediated gene regulation
within the nucleus ; The dynamics of miRNA-mediated gene regulation ; MicroRNA abundance
and turnover ; Concluding remarks ; References ; Chapter 2 microRNA in cancer:
An overview ; The dawn of miRNAs in human biology ; First reported miRNA cancer-associated
alterations ; The age of discovery: Microarrays and miRNA cancer signatures ; Functional
classification of miRNA: The line between tumor suppressor and oncomiRs ; Development
of miRNA as biomarkers ; The transition of miRNA into clinics ; Conclusion and future
perspectives ; References ; Chapter 3 miR-15/16 in human malignancies ; 13q deletions
in CLL and miR-15/16 ; Other mechanisms of miR-15/16 dysregulation ; Interplay between
ROR1, Bcl2, and miR-15/16 in CLL ; miR-15/16 in mice ; miR-15/16 in human AML and
MDS ; miR-15/16 in solid cancers ; References ; Chapter 4 microRNAs and tumor suppressor
p53 regulation ; p53 and its signaling pathway ; GOF mutant p53 in cancer ; miRNAs
regulated by wild-type p53 ; miRNAs that directly regulate p53 ; miRNAs that indirectly
regulate p53 ; miRNAs regulated by GOF mutp53 ; Conclusion ; References.
Chapter 5 MicroRNA involvement in invasion and metastasis ; Introduction-The process
of metastasis ; Direct regulation of metastasis ; Metastasis-promoting miRNAs ;
Metastasis-Suppressing miRNAs ; Indirect regulation of metastasis ; Regulation of
miRNA biosynthesis ; RNA-RNA interaction-based miRNA regulation ; Translational
application of metastasis-associated miRNAs ; Noninvasive biomarkers ; miRNAs as
therapeutics ; Conclusions and perspectives ; Acknowledgment ; References ; Chapter
6 microRNAs and metabolism ; Introduction ; Trafficking and consumption of glucose
; NcRNAs regulate glucose trafficking in cancer cells by altering GLUT levels ; NcRNAs
regulate key glycolytic enzymes ; Branched pathways of glycolysis ; NcRNAs can influence
glucose metabolism by regulating cancer-associated signaling pathways ; PI3K/Akt/mTOR
and HIF-1 signaling pathway ; p53 signaling pathway ; Conclusion and future perspectives
; References ; Chapter 7 microRNAs in inflammation processes ; Introduction ; MiRNA
biogenesis and functions ; Inflammation and mechanism of activation ; miRNAs in
inflammatory disease ; Chronic respiratory diseases ; Cystic fibrosis (CF) ; Chronic
obstructive pulmonary disease (COPD) ; Asthma ; Cardiovascular diseases ; Atherosclerosis
; Myocardial infarction (MI) and ischemia reperfusion injury (MIRI) ; Autoimmune
diseases ; Systemic lupus erythematosus (SLE) ; Rheumatoid arthritis (RA) ; Multiple
sclerosis (MS) ; Cancer ; Colorectal cancer (CRC) ; Lung cancer (LC) ; Prostate
cancer (PC) ; Conclusion ; References ; Section B: miRNAs methodologies ; Chapter
8 Wet-lab methods for miRNA analysis ; Introduction ; Methods for miRNA discovery
and detection ; Northern blot ; Hybridization microarrays ; Quantitative PCR ;
Next-generation sequencing ; Functional miRNA analysis.
Classical target validation methods: Reporter genes and RISC immunoprecipitation
; High-throughput methods for target identification ; Functional validation ; Final
remarks ; Acknowledgments ; References ; Chapter 9 Bioinformatics utilities, web
resources and integrative strategies for the analysis of miRNA regulatory networks
; Introduction ; Target prediction algorithms ; Single predictors ; Multiple predictors
; In silico functional assessment of miRNAs: Tips and tricks ; Functional analysis
of miRNAs associated with survival time in lung adenocarcinoma: A test case ; Conclusions
; Acknowledgments ; References ; Chapter 10 Computational resources for analysis
of miRNA targetome ; Introduction ; miRNA target databases ; miRNA target databases
for human ; miRNA target databases for other species ; miRNA algorithms ; miRNA
target prediction for humans ; miRNA target prediction for other species ; miRNA
target prediction for plants ; Conclusion ; References ; Chapter 11 miRNA bioinformatics
and pathway analysis ; The microRNA synergy ; Role of microRNAs in biological signaling
pathways ; Pathways: The manually curated maps of the cell interactome ; The miRNA
interactome ; miRNA pathway analysis methods ; ORA on miRNA targets ; FCS on miRNA
targets ; Topological approaches of pathway analysis with miRNAs ; Computational
tools for miRNA pathway analyses ; Conclusions ; Funding ; References ; Section
C: miRNAs involvement in therapeutics/theranostics ; Chapter 12 Opportunities of
miRNAs in cancer therapeutics ; Introduction ; MicroRNAs in cancer. OncomiRs and
tumor-suppressor miRNAs ; Alterations in miRNAs and their appeal for cancer therapy
; MicroRNA-based drug design ; Choosing the therapeutic strategy: miRNA mimics, antagomiRs,
and more ; Chemical modifications of RNA-based drugs.
Delivery of RNA-based drugs ; Chemical modifications ; Liposomes, micelles, and
exosomes ; Nanoparticles ; Viral vectors ; Bacteria-based vectors (EDV nanocells)
; MicroRNA-based therapeutics in the current clinic ; MRX34 ; Cobomarsen ; TargomiRs
; Remlarsen ; Other preclinical studies ; The future of miRNAs in the clinic ;
Current challenges in the use of miRNAs ; Quick degradation in the bloodstream ;
Extrahepatic delivery to tumor site ; Limited tissue penetration ; Endocytosis and
endosome entrapment ; Off-targets and side effects ; Other challenges ; Future
perspectives ; References ; Section D: miRNAs involvement in human cancer: Pathophysiology
and translational opportunities ; Chapter 13 Pathophysiology roles and translational
opportunities of miRNAs in acute leukemias ; Introduction ; MiRNAs involved in the
pathogenesis of AML ; miRNAs as biomarkers ; miRNAs in chemoresistance ; miRNAs
as therapeutic targets ; Role of miR-15/16 clusters in AML pathogenesis ; Conclusions
; References ; Chapter 14 Pathophysiology roles and translational opportunities of
miRNAs in CLL ; MicroRNAs and the cellular origin of CLL cells ; MicroRNAs and CLL
genetics ; microRNAs in proliferation and survival of CLL cells ; microRNAs and
BCR signaling ; MicroRNAs and microenvironment ; MicroRNAs and apoptosis ; Translational
opportunities ; References ; Chapter 15 Pathophysiology roles and translational
opportunities of miRNAs in lymphoma ; Summary ; miRNAs and pathophysiology ; miRNAs
regulate the expression of genes that promote B-cell differentiation ; Lymphomagenesis
; DLBCL and miRNA ; MZL and miRNA ; Diagnosis ; Prognosis ; References ; Chapter
16 Pathophysiology roles and translational opportunities of miRNAs in breast cancer
; Breast physiology and pathology ; Breast physiology ; Breast pathology.
